Frances R Levin1, C Jean Choi2, Martina Pavlicova3, John J Mariani4, Amy Mahony5, Daniel J Brooks5, Edward V Nunes4, John Grabowski6. 1. New York State Psychiatric Institute, Division of Substance Abuse, 1051 Riverside Drive, New York, NY 10032, USA; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA. Electronic address: frances.levin@nyspi.columbia.edu. 2. New York State Psychiatric Institute, Division of Biostatistics, 1051 Riverside Drive, New York, NY 10032, USA. 3. Department of Biostatistics, Mailman School of Public Health at Columbia University, 722 West 168th Street, New York, NY 10032, USA. 4. New York State Psychiatric Institute, Division of Substance Abuse, 1051 Riverside Drive, New York, NY 10032, USA; Department of Psychiatry, College of Physicians and Surgeons of Columbia University, 630 West 168th Street, New York, NY 10032, USA. 5. New York State Psychiatric Institute, Division of Substance Abuse, 1051 Riverside Drive, New York, NY 10032, USA. 6. Department of Psychiatry F282/2A West, Medical School, University of Minnesota, 2450 Riverside Avenue, Minneapolis, MN 55454, USA.
Abstract
BACKGROUND: Attention-deficit hyperactivity disorder (ADHD) is overrepresented among individuals seeking treatment for substance use disorders. We previously reported that treatment with extended release mixed amphetamine salts (MAS-XR) increased abstinence, compared to placebo, among patients with co-occurring ADHD and cocaine dependence. This secondary analysis investigates the temporal relationship between ADHD improvement and cocaine abstinence in the first six weeks of the trial. METHODS: The study was a three-arm, randomized, double-blinded, placebo-controlled, 14-week trial comparing MAS-XR (60 mg or 80 mg daily) versus placebo among 126 participants with ADHD and cocaine dependence. An autoregressive cross-lagged structural equation model was fit and evaluated weekly ADHD improvement (defined as ≥30% reduction in the Adult ADHD Investigator Symptom Rating Scale) and urine-confirmed abstinence over the first six weeks. RESULTS: The proportion of patients with each of the possible overall patterns of response was: ADHD improves before cocaine abstinence: 24%; Cocaine abstinence occurs before ADHD improvement: 12%; ADHD improvement and abstinence occur during the same week: 6%; ADHD improves but abstinence never achieved: 34%; Abstinence achieved but ADHD never improves: 6%; Neither ADHD improvement nor abstinence: 18%. A significant cross-lagged association was found; subjects with ADHD improvement at week 2 had significantly higher odds of cocaine abstinence at week 3 (p = .014). CONCLUSION: When treating co-occurring ADHD and cocaine dependence with stimulant medication, abstinence is most likely preceded by improvement in ADHD, which tends to occur early with medication treatment. Other observed temporal patterns suggest the potential complexity of the relationship between ADHD and cocaine dependence.
RCT Entities:
BACKGROUND:Attention-deficit hyperactivity disorder (ADHD) is overrepresented among individuals seeking treatment for substance use disorders. We previously reported that treatment with extended release mixed amphetamine salts (MAS-XR) increased abstinence, compared to placebo, among patients with co-occurring ADHD and cocaine dependence. This secondary analysis investigates the temporal relationship between ADHD improvement and cocaine abstinence in the first six weeks of the trial. METHODS: The study was a three-arm, randomized, double-blinded, placebo-controlled, 14-week trial comparing MAS-XR (60 mg or 80 mg daily) versus placebo among 126 participants with ADHD and cocaine dependence. An autoregressive cross-lagged structural equation model was fit and evaluated weekly ADHD improvement (defined as ≥30% reduction in the Adult ADHD Investigator Symptom Rating Scale) and urine-confirmed abstinence over the first six weeks. RESULTS: The proportion of patients with each of the possible overall patterns of response was: ADHD improves before cocaine abstinence: 24%; Cocaine abstinence occurs before ADHD improvement: 12%; ADHD improvement and abstinence occur during the same week: 6%; ADHD improves but abstinence never achieved: 34%; Abstinence achieved but ADHD never improves: 6%; Neither ADHD improvement nor abstinence: 18%. A significant cross-lagged association was found; subjects with ADHD improvement at week 2 had significantly higher odds of cocaine abstinence at week 3 (p = .014). CONCLUSION: When treating co-occurring ADHD and cocaine dependence with stimulant medication, abstinence is most likely preceded by improvement in ADHD, which tends to occur early with medication treatment. Other observed temporal patterns suggest the potential complexity of the relationship between ADHD and cocaine dependence.
Authors: José Pérez de Los Cobos; Núria Siñol; Carmen Puerta; Vanessa Cantillano; Cristina López Zurita; Joan Trujols Journal: Psychiatry Res Date: 2010-05-26 Impact factor: 3.222
Authors: Katelijne van Emmerik-van Oortmerssen; Geurt van de Glind; Maarten W J Koeter; Steve Allsop; Marc Auriacombe; Csaba Barta; Eli Torild H Bu; Yuliya Burren; Pieter-Jan Carpentier; Susan Carruthers; Miguel Casas; Zsolt Demetrovics; Geert Dom; Stephen V Faraone; Melina Fatseas; Johan Franck; Brian Johnson; Máté Kapitány-Fövény; Sharlene Kaye; Maija Konstenius; Frances R Levin; Franz Moggi; Merete Møller; J Antoni Ramos-Quiroga; Arild Schillinger; Arvid Skutle; Sofie Verspreet; Wim van den Brink; Robert A Schoevers Journal: Addiction Date: 2013-11-20 Impact factor: 6.526
Authors: Frances R Levin; Suzette M Evans; Daniel J Brooks; Aparna S Kalbag; Fatima Garawi; Edward V Nunes Journal: Drug Alcohol Depend Date: 2005-08-15 Impact factor: 4.492
Authors: Eugene C Somoza; Theresa M Winhusen; T Peter Bridge; John P Rotrosen; Douglas G Vanderburg; Judy M Harrer; Juris P Mezinskis; Margaret A Montgomery; Domenic A Ciraulo; Lawson R Wulsin; Jera A Barrett Journal: J Addict Dis Date: 2004
Authors: Thomas J Spencer; Lenard A Adler; Keith E Saylor; Thomas E Brown; James A Holdnack; Kory J Schuh; Paula T Trzepacz; Douglas K Kelsey Journal: J Atten Disord Date: 2009-09-30 Impact factor: 3.256
Authors: Greg W Mattingly; Richard H Weisler; Joel Young; Ben Adeyi; Bryan Dirks; Thomas Babcock; Robert Lasser; Brian Scheckner; David W Goodman Journal: BMC Psychiatry Date: 2013-01-29 Impact factor: 3.630
Authors: Enrico Capuzzi; Martina Capellazzi; Alice Caldiroli; Francesca Cova; Anna Maria Auxilia; Paola Rubelli; Ilaria Tagliabue; Francesco Giuseppe Zanvit; Gianluca Peschi; Massimiliano Buoli; Massimo Clerici Journal: Healthcare (Basel) Date: 2022-01-18